{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:42:24Z","timestamp":1790952144996,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"publisher","award":["9-2020-0046"],"award-info":[{"award-number":["9-2020-0046"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>With antidepressants (ADs) having minimal therapeutic effects during the initial weeks of treatment, benzodiazepines (BZDs) are concomitantly used to alleviate depressive symptoms of insomnia or anxiety. However, with mortality risks associated with this concomitant use yet to be examined, it remains unclear as to whether this concomitant therapy offers any benefits in treating depression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a population-based cohort study using South Korea\u2019s nationwide healthcare database from 2002 to 2017. Of 2.6 million patients with depression, we identified 612,729 patients with incident depression and newly prescribed ADs or BZDs, by excluding those with a record of diagnosis or prescription within the 2\u00a0years prior to their incident diagnosis. We classified our study cohort into two discrete groups depending on the type of AD treatment received within 6\u00a0months of incident diagnosis\u2014AD monotherapy and AD plus BZD (AD+BZD) therapy. We matched our study cohort in a 1:1 ratio using propensity scores to balance baseline characteristics and obtain comparability among groups. The primary outcome was all-cause mortality, and patients were followed until the earliest of outcome occurrence or end of the study period. We conducted multivariable Cox proportional hazards regression analysis to estimate adjusted hazards ratios (HRs) with 95% confidence intervals (CIs) for the risk of mortality associated with AD+BZD therapy versus AD monotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The propensity score-matched cohort had 519,780 patients with 259,890 patients in each group, where all baseline characteristics were well-balanced between the two groups. Compared to AD monotherapy, AD+BZD therapy was associated with an increased risk of all-cause mortality (adjusted HR, 1.04; 95% CI, 1.02 to 1.06).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Concomitantly initiating BZDs with ADs was associated with a moderately increased risk of mortality. Clinicians should therefore exercise caution when deciding to co-prescribe BZDs with ADs in treating depression, as associated risks were observed.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-020-01854-w","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T03:12:43Z","timestamp":1607483563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Risk of mortality associated with concomitant antidepressant and benzodiazepine therapy among patients with depression: a population-based cohort study"],"prefix":"10.1186","volume":"18","author":[{"given":"Han Eol","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha-Lim","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Sun","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,9]]},"reference":[{"key":"1854_CR1","volume-title":"Health statistics and information systems","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Global Health Estimates 2016: disease burden by cause, age, sex, by country and by region, 2000-2016. In: Health statistics and information systems; 2018."},{"issue":"9","key":"1854_CR2","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1002\/pds.3255","volume":"21","author":"C Wu","year":"2012","unstructured":"Wu C, Shau W, Chan H, Lee Y, Lai Y, Lai M. Utilization of antidepressants in Taiwan: a nationwide population-based survey from 2000 to 2009. Pharmacoepidemiol Drug Saf. 2012;21(9):980\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"1854_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.4088\/JCP.13m08443","volume":"75","author":"R Mojtabai","year":"2014","unstructured":"Mojtabai R, Olfson M. National trends in long-term use of antidepressant medications: results from the U.S. National Health and Nutrition Examination Survey. J Clin Psychiatry. 2014;75(2):169\u201377.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"1854_CR4","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00228-014-1803-x","volume":"71","author":"R Noordam","year":"2015","unstructured":"Noordam R, Aarts N, Verhamme K, Sturkenboom M, Stricker B, Visser L. Prescription and indication trends of antidepressant drugs in the Netherlands between 1996 and 2012: a dynamic population-based study. Eur J Clin Pharmacol. 2015;71(3):369\u201395.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1485","key":"1854_CR5","first-page":"52","volume":"131","author":"S Wilkinson","year":"2018","unstructured":"Wilkinson S, Mulder R. Antidepressant prescribing in New Zealand between 2008 and 2015. N Z Med J. 2018;131(1485):52\u20139.","journal-title":"N Z Med J"},{"issue":"11","key":"1854_CR6","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.4088\/JCP.10m06419","volume":"72","author":"R Uher","year":"2011","unstructured":"Uher R, Mors O, Rietschel M, Rajewska-Rager A, Petrovic A, Zobel A, Henigsberg N, Mendlewicz J, Aitchison K, Farmer A, et al. Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. J Clin Psychiatry. 2011;72(11):1478\u201384.","journal-title":"J Clin Psychiatry"},{"key":"1854_CR7","doi-asserted-by":"crossref","unstructured":"Furukawa T, Streiner D, Young L. Antidepressant plus benzodiazepine for major depression. Cochrane Database Syst Rev. 2001;(2):CD001026.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/11405972\/.","DOI":"10.1002\/14651858.CD001026"},{"issue":"6","key":"1854_CR8","first-page":"CD001026","volume":"6","author":"Y Ogawa","year":"2019","unstructured":"Ogawa Y, Takeshima N, Hayasaka Y, Tajika A, Watanabe N, Streiner D, Furukawa T. Antidepressants plus benzodiazepines for adults with major depression. Cochrane Database Syst Rev. 2019;6(6):CD001026.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"1854_CR9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/jamapsychiatry.2017.1273","volume":"74","author":"G Bushnell","year":"2017","unstructured":"Bushnell G, Sturmer T, Gaynes B, Pate V, Miller M. Simultaneous antidepressant and benzodiazepine new use and subsequent long-term benzodiazepine use in adults with depression, United States, 2001-2014. JAMA Psychiatry. 2017;74(7):747\u201355.","journal-title":"JAMA Psychiatry"},{"key":"1854_CR10","first-page":"e04","volume":"71","author":"J Davidson","year":"2017","unstructured":"Davidson J. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry. 2017;71:e04.","journal-title":"J Clin Psychiatry"},{"key":"1854_CR11","doi-asserted-by":"crossref","unstructured":"2019 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel: American Geriatrics Society 2019 Updated AGS beers criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2019, 67(4):674\u2013694.","DOI":"10.1111\/jgs.15767"},{"issue":"6","key":"1854_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/070674371105600609","volume":"56","author":"N Gisev","year":"2011","unstructured":"Gisev N, Hartikainen S, Chen T, Korhonen M, Bell J. Mortality associated with benzodiazepines and benzodiazepine-related drugs among community-dwelling older people in Finland: a population-based retrospective cohort study. Can J Psychiatr. 2011;56(6):377\u201381.","journal-title":"Can J Psychiatr"},{"key":"1854_CR13","doi-asserted-by":"publisher","first-page":"j2941","DOI":"10.1136\/bmj.j2941","volume":"358","author":"E Patorno","year":"2017","unstructured":"Patorno E, Glynn R, Levin R, Lee M, Huybrechts K. Benzodiazepines and risk of all cause mortality in adults: cohort study. BMJ. 2017;358:j2941.","journal-title":"BMJ"},{"issue":"2","key":"1854_CR14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0165-0327(00)00254-8","volume":"65","author":"T Furukawa","year":"2001","unstructured":"Furukawa T, Streiner D, Young L. Is antidepressant-benzodiazepine combination therapy clinically more useful? A meta-analytic study. J Affect Disord. 2001;65(2):173\u20137.","journal-title":"J Affect Disord"},{"issue":"3","key":"1854_CR15","first-page":"799","volume":"46","author":"S Seong","year":"2016","unstructured":"Seong S, Kim Y-Y, Khang Y-H, Park J, Kang H-J, Lee H, Do C-H, Song J-S, Bang J, Ha S, et al. Data resource profile: the national health information database of the National Health Insurance Service in South Korea. Int J Epidemiol. 2016;46(3):799\u2013800.","journal-title":"Int J Epidemiol"},{"issue":"11","key":"1854_CR16","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Jean-Christophe L, Duncan Saunders L, Beck CA, Thomas E, Feasby GWA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139.","journal-title":"Med Care"},{"issue":"12","key":"1854_CR17","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/aje\/kwj149","volume":"163","author":"M Brookhart","year":"2006","unstructured":"Brookhart M, Schneeweiss S, Rothman K, Glynn R, Avorn J, St\u00fcrmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163(12):1149\u201356.","journal-title":"Am J Epidemiol"},{"issue":"6","key":"1854_CR18","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/sim.6004","volume":"33","author":"P Austin","year":"2014","unstructured":"Austin P. A comparison of 12 algorithms for matching on the propensity score. Stat Med. 2014;33(6):1057\u201369.","journal-title":"Stat Med"},{"issue":"3","key":"1854_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"P Austin","year":"2011","unstructured":"Austin P. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399\u2013424.","journal-title":"Multivariate Behav Res"},{"key":"1854_CR20","unstructured":"Parsons L. Reducing bias in a propensity score matched-pair sample using greedy matching techniques [Internet]. Cary NC: SAS Institute Inc., Proceedingsof the Twenty-Sixth Annual SAS Users Group International Conference; 2001. p. 214\u201326. Available from http:\/\/www2.sas.com\/proceedings\/sugi26\/p214-26.pdf."},{"key":"1854_CR21","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","volume":"38","author":"PCA","year":"2009","unstructured":"PCA. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul C. 2009;38:1228\u201334.","journal-title":"Commun Stat Simul C"},{"issue":"8","key":"1854_CR22","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.eurpsy.2015.09.003","volume":"30","author":"T Kurko","year":"2015","unstructured":"Kurko T, Saastamoinen L, T\u00e4hk\u00e4p\u00e4\u00e4 S, Tuulio-Henriksson A, Taiminen T, Tiihonen J, Airaksinen M, Hietala J. Long-term use of benzodiazepines: definitions, prevalence and usage patterns - a systematic review of register-based studies. Eur J Psychiatry. 2015;30(8):1037\u201347.","journal-title":"Eur J Psychiatry"},{"issue":"1","key":"1854_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/1740774511420743","volume":"9","author":"M Hernan","year":"2012","unstructured":"Hernan M, Hernandez-Diaz S. Beyond the intention to treat in comparative effectiveness research. Clin Trials. 2012;9(1):48\u201355.","journal-title":"Clin Trials"},{"issue":"5","key":"1854_CR24","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/CIRCOUTCOMES.113.000359","volume":"6","author":"M Brookhart","year":"2013","unstructured":"Brookhart M, Wyss R, Layton J, Sturmer T. Propensity score methods for confounding control in non-experimental research. Circ Cardiovasc Qual Outcomes. 2013;6(5):604\u201311.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"4","key":"1854_CR25","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"T VanderWeele","year":"2017","unstructured":"VanderWeele T, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268\u201374.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1854_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1176\/appi.ajp.2016.16030336","volume":"174","author":"W McCall","year":"2017","unstructured":"McCall W, Benca R, Rosenquist P, Riley M, McCloud L, Newman J, Case D, Rumble M, Krystal A. Hypnotic medications and suicide: risk, mechanisms, mitigation, and the FDA. Am J Psychiatry. 2017;174(1):18\u201325.","journal-title":"Am J Psychiatry"},{"key":"1854_CR27","doi-asserted-by":"crossref","unstructured":"Dodds T. Prescribed benzodiazepines and suicide risk: a review of the literature. Prim Care Companion CNS Disord .2017;19(2):16r02037.","DOI":"10.4088\/PCC.16r02037"},{"issue":"8","key":"1854_CR28","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2165\/11533170-000000000-00000","volume":"24","author":"B Smink","year":"2010","unstructured":"Smink B, Egberts A, Lusthof K, Uges D, de Gier J. The relationship between benzodiazepine use and traffic accidents: a systematic literature review. CNS Drugs. 2010;24(8):639\u201353.","journal-title":"CNS Drugs"},{"key":"1854_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.maturitas.2017.04.002","volume":"101","author":"M D\u00edaz-Guti\u00e9rrez","year":"2017","unstructured":"D\u00edaz-Guti\u00e9rrez M, Mart\u00ednez-Cengotitabengoa M, de Adana E, Cano A, Mart\u00ednez-Cengotitabengoa M, Besga A, Segarra R, Gonz\u00e1lez-Pinto A. Relationship between the use of benzodiazepines and falls in older adults: a systematic review. Maturitas. 2017;101:17\u201322.","journal-title":"Maturitas"},{"issue":"3","key":"1854_CR30","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/10401230802177698","volume":"20","author":"N Youssef","year":"2008","unstructured":"Youssef N, Rich C. Does acute treatment with sedatives\/hypnotics for anxiety in depressed patients affect suicide risk? A literature review. Ann Clin Psychiatry. 2008;20(3):157\u201369.","journal-title":"Ann Clin Psychiatry"},{"issue":"7","key":"1854_CR31","first-page":"A466","volume":"17","author":"A Jamotte","year":"2014","unstructured":"Jamotte A, Clay E, Onishi Y, Aball\u00e9a S, Toumi M. Treatment patterns and health care costs in patients with depression treated with antidepressant only or combined with benzodiazepine: results from a Japanese claims database analysis. Value Health. 2014;17(7):A466.","journal-title":"Value Health"},{"issue":"5","key":"1854_CR32","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1017\/S1041610217002563","volume":"31","author":"X Zhong","year":"2019","unstructured":"Zhong X, Wang F, Zhang Q, Ungvari G, Ng C, Chiu H, Si T, Sim K, Avasthi A, Grover S, et al. Concurrent benzodiazepine use in older adults treated with antidepressants in Asia. Int Psychogeriatr. 2019;31(5):685\u201391.","journal-title":"Int Psychogeriatr"},{"issue":"10","key":"1854_CR33","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0895-4356(02)00457-2","volume":"55","author":"K van Dijk","year":"2002","unstructured":"van Dijk K, de Vries C, ter Huurne K, van den Berg P, Brouwers J, de Jong-van den Berg L. Concomitant prescribing of benzodiazepines during antidepressant therapy in the elderly. J Clin Epidemiol. 2002;55(10):1049\u201353.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"1854_CR34","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/YIC.0000000000000019","volume":"29","author":"HJ Jeon","year":"2014","unstructured":"Jeon HJ, Walker RS, Inamori A, Hong JP, Cho MJ, Baer L, Clain A, Fava M, Mischoulon D. Differences in depressive symptoms between Korean and American outpatients with major depressive disorder. Int Clin Psychopharmacol. 2014;29(3):150\u20136.","journal-title":"Int Clin Psychopharmacol"},{"key":"1854_CR35","doi-asserted-by":"crossref","unstructured":"Lim B, Sproule B, Zahra Z, Sunderji N, Kennedy S, Rizvi S. Understanding the effects of chronic benzodiazepine use in depression: a focus on neuropharmacology. Int Clin Psychopharmacol. 2020;35(5):243\u201353.","DOI":"10.1097\/YIC.0000000000000316"},{"issue":"12","key":"1854_CR36","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1111\/j.1360-0443.2012.03975.x","volume":"107","author":"L Manthey","year":"2012","unstructured":"Manthey L, Lohbeck M, Giltay E, van Veena T, Zitman F, Penninx B. Correlates of benzodiazepine dependence in the Netherlands study of depression and anxiety. Addiction. 2012;107(12):2173\u201382.","journal-title":"Addiction"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-020-01854-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12916-020-01854-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-020-01854-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T08:18:12Z","timestamp":1607501892000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-020-01854-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1854"],"URL":"https:\/\/doi.org\/10.1186\/s12916-020-01854-w","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"31 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Institutional Review Board (IRB) of Sungkyunkwan University (SKKU 2019-01-009) and obtaining informed consent from the study population was waived by the IRB.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Mr. Jeong reports receipt of research funding from the National Research Foundation of South Korea, outside the submitted work. Mr. Oh reports receipt of research funding from the National Research Foundation of South Korea, outside the submitted work. Dr. Kim reports receipt of research grants from the National Research Foundation of South Korea and research funding or honoraria from the pharmaceutical companies including Lundbeck, Esai, and Handok, outside the submitted work. Dr. Shin reports receipt of research funding from the Ministry of Food and Drug Safety, Ministry of Health and Welfare, National Research Foundation, and Government-wide R&D Fund for Infectious Disease Research of South Korea and grants from pharmaceutical companies including Amgen, Pfizer, Hoffmann-La Roche, Dong-A ST, and Yungjin, outside the submitted work. No other disclosures were reported.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"387"}}